Retrospective validation of PRECISION study at 10-years and contribution of PSA density for first biopsies indication in case of negative MRI

Retrospective validation of PRECISION study at 10-years and contribution of PSA density for first biopsies indication in case of negative MRI

Bibliographic Details
Main Authors:	J. Buisset, P. Puech, A. Villers, J. Olivier
Format:	Article
Language:	English
Published:	Elsevier 2020-07-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168320337514

Similar Items

Negative pre-biopsy magnetic resonance imaging and risk of significant prostate cancer: Baseline and long-term follow-up results
by: J. Buisset, et al.
Published: (2020-11-01)

The negative predictive value of PSA density in the MRI prostate era
by: N. ODwyer, et al.
Published: (2020-07-01)

Indeterminate mpMRI lesions: Evaluating the optimal PSA density threshold for prostate biopsy
by: D.T. Reddy, et al.
Published: (2020-07-01)

Optimal PSA Threshold for Obtaining MRI-Fusion Biopsy in Biopsy-Naïve Patients
by: Luke L. Wang, et al.
Published: (2021-01-01)

The value of PSA density in PI-RADS 3 lesions on multiparametric MRI - a strategy to avoid unnecessary prostate biopsies
by: M. Görtz, et al.
Published: (2020-07-01)

Evaluation the contribution of PSA, DRE and TRUS in prostate biopsy
by: Hao-Shuoh Jeng, et al.
Published: (2004)

The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study
by: Abraham M. Getaneh, et al.
Published: (2021-01-01)

Targeted 11C–choline PET-CT/TRUS software fusion-guided prostate biopsy in men with persistently elevated PSA and negative mpMRI after previous negative biopsy
by: Massimo Lazzeri, et al.
Published: (2017-11-01)

Predictors of Clinically Significant Prostate Cancer: A Comparative Study of PSA, PSA Density, and MRI Parameters
by: Mehmet Coşkun, et al.
Published: (2021-02-01)

Multiparametric MRI-Targeted TRUS Prostate Biopsies Using Visual Registration
by: Philippe Puech, et al.
Published: (2014-01-01)

Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and 10 ng/ml
by: Emerson P. Gregorio, et al.
Published: (2007-04-01)

Validating fPSA Glycoprofile as a Prostate Cancer Biomarker to Avoid Unnecessary Biopsies and Re-Biopsies
by: Tomas Bertok, et al.
Published: (2020-10-01)

Performance of PSA and of PSA density in the diagnosis of prostate carcinoma
by: Antonio Carlos Pereira Martins, et al.
Published: (2002-01-01)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
by: Nigel P. Murray, et al.
Published: (2014-01-01)

PSA levels of 4.0 - 10 ng/ml and negative digital rectal examination: antibiotic therapy versus immediate prostate biopsy
by: Avraham Shtricker, et al.
Published: (2009-10-01)

Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4-10 ng ml-1
by: Lincoln GL Tan, et al.
Published: (2017-01-01)

Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with PSA levels between 2.6 and 10.0 ng/mL
by: Hugo A. Socrates Castro, et al.

The Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial Negative Biopsy
by: Nadeem Shaida, et al.
Published: (2009-01-01)

Multiparametric MRI in the PSA Screening Era
by: Arvin K. George, et al.
Published: (2014-01-01)

Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA>4ng/mL, or with PIN biopsy result
by: Alexandros Fiamegos, et al.

Prostate cancer detection after negative biopsy: MRI, biomarker or systematic biopsy
by: D. Cheung, et al.
Published: (2020-07-01)

MRI-Targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: Follow-up of a precision trial-like retrospective cohort
by: S. Luzzago, et al.
Published: (2020-10-01)

Does PSA reduction after antibiotic therapy permits postpone prostate biopsy in asymptomatic men with PSA levels between 4 and 10ng/mL?
by: W. F. S. Busato, et al.
Published: (2015-04-01)

Evaluation of PCA3 and multiparametric MRI’s: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL
by: Sezgin Okcelik, et al.
Published: (2016-06-01)

The effect on the sensitivities of PSA and PSA-age volume score of IPSS and nocturia in predicting positive prostate biopsy findings
by: O. Üçer, et al.
Published: (2017-06-01)

CUT-OFF POINT OF PSA AND PSA DENSITY IN PROSTATE CANCER SUSPECTED PATIENTS
by: Daniel Simanjuntak, et al.
Published: (2016-03-01)

Evaluation of PSA density for the detection of clinically significant prostate cancer in biopsy-naive patients with PI-RADS 3 lesions
by: A. Iseppi, et al.
Published: (2020-10-01)

MRI-targeted or standard biopsy for prostate cancer diagnosis in biopsy naïve patients. The PRECISION trial follow-up
by: S. Luzzago, et al.
Published: (2020-07-01)

Malakoplakia of the prostate diagnosed by elevated PSA level and transrectal prostate biopsy
by: Sacit Nuri Görgel, et al.
Published: (2011-04-01)

Prostate biopsy for elevated prostate specific antigen (PSA) - Indian perspective
by: N Ragavan
Published: (2014-01-01)

Association of very low PSA with increased metastases and death in patients with biopsy Gleason score 8-10 prostate cancer
by: R.S. Pompe, et al.
Published: (2020-07-01)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
by: Tsung-Hsin Chang, et al.
Published: (2020-10-01)

Systematic biopsy is unnecessary for the detection of clinically significant prostate cancer in men with PIRADS 5 and PSA density greater than 15%
by: A. Tafuri, et al.
Published: (2020-10-01)

Case Report: Prostate Adenocarcinoma With Mucinous Features of Normal-Level Serum PSA, Atypical Imaging, Biopsy-Negative, and Peculiar Urethrocystoscopic Manifestation
by: Yao Zhang, et al.
Published: (2020-12-01)

AGE, TOTAL PSA, PSA DENSITY AND GLEASON SCORE, TAUS AS PREDICTIVE FACTORS IN PATIENTS WITH PROSTATE CANCER
by: Daruqutni Albar, et al.
Published: (2016-03-01)

Repeat prostate biopsy strategies after initial negative biopsy: meta-regression comparing cancer detection of transperineal, transrectal saturation and MRI guided biopsy.
by: Adam W Nelson, et al.
Published: (2013-01-01)

The importance of PSA-Density in active surveillance for prostate cancer
by: Caner Ediz, et al.
Published: (2020-06-01)

Incidence of histological prostatitis and its correlation with PSA density
by: Affonso Celso Piovesan, et al.
Published: (2009-11-01)

Raising cut-off value of prostate specific antigen (PSA) for biopsy in symptomatic men in India to reduce unnecessary biopsy
by: Shalini Agnihotri, et al.
Published: (2014-01-01)

Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI
by: Linghui Liang, et al.
Published: (2021-03-01)